SCHEMBL2660111

SCHEMBL2660111

Oc1ccc2[nH]nc(Nc3nccs3)c2c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.58
MAPK1 P28482 3/20 0.41
FADS1 O60427 4/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
MAP2K4 P45985 2/20 0.37
MAPKAPK2 P49137 2/20 0.37
MAPKAPK3 Q16644 2/20 0.37
MAPK6 Q16659 2/20 0.37
MAPKAPK5 Q8IW41 1/20 0.37
MAPK8 P45983 1/20 0.36
LMNA P02545 1/20 0.35
RIPK2 O43353 1/20 0.35
BRAF P15056 1/20 0.34
PDPK1 O15530 1/20 0.34
HSP90AB1 P08238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660635 0.84 GRM4 (0.58) GRM4MAPK1FADS1JAK2RIPK2
SCHEMBL2667982 0.84 GRM4 (0.58) GRM4MAPK1FADS1LMNA
SCHEMBL2660645 0.84 GRM4 (0.58) GRM4MAPK1FADS1LMNA
SCHEMBL2662190 0.83 GRM4 (0.54) GRM4MAPK1FADS1JAK2JAK1
SCHEMBL2668091 0.82 GRM4 (0.55) GRM4MAPK1FADS1JAK2JAK1
SCHEMBL2661297 0.81 GRM4 (0.52) GRM4MAPK1JAK2JAK1TYK2
SCHEMBL2667991 0.81 GRM4 (0.52) GRM4MAPK1FADS1JAK2JAK1
SCHEMBL2660583 0.81 GRM4 (0.54) GRM4MAPK1FADS1MAP2K4MAPKAPK2
SCHEMBL2654720 0.81 GRM4 (0.54) GRM4MAPK1FADS1LMNA
SCHEMBL2662181 0.81 GRM4 (0.54) GRM4MAPK1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP claimed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US claimed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO claimed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244169-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GRM4 1511/4885MAPK1 1276/4885FADS1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.